SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
HHSC to Add New Qulipta® Indication to Clinical Prior Authorization
Date: June 20, 2023
Attention: All Providers
Effective Date: June 27, 2023
Call to action:Texas Children’s Health Plan (TCHP) would like to let providers know that effective June 27, 2023, Texas Health and Human Services (HHSC) will follow the Food and Drug Administration’s recent approval of new indication for atogepant (Qulipta®), to prevent chronic migraine in adults.
How this impacts providers: Starting June 27, 2023, TCHP will implement the new indication for atogepant (Qulipta®) to prevent chronic migraine in adults. The new criteria is available on the HHSC website and can be viewed here: Calcitonin Gene-Related Peptide Receptor (CGRP).
Next steps for providers: Prescribers should share this communication with their staff. Provider must submit documentation, including but not limited to: office chart notes, lab results, pertinent clinical information, etc. supporting that the member has met all appropriate criteria in support for Qulipta® approval.
